Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.

Latest from Vibha Ravi

How To Speed Up MLR Reviews: A Master Class By J&J, UCB, ex-Takeda Heads

A panel of experts from J&J, UCB and Takeda deliberated on the use of AI and internal processes to strike the right balance between speed and accuracy in MLR reviews that could protect a company from serious repercussions

Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.

As Novo Spars Over Semaglutide Capacity, Strides To Arm GLP-1 Generics Cos Ahead Of LoEs

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting

Sumitomo, Ex-Pfizer Exec On Lipitor Lessons, Lady Gaga Connect For Go-To-Market Strategy

CEO of Sumitomo Pharma America unit, Adele M. Gulfo, draws from experiences working across companies including Pfizer, to advise on go-to-market strategies for a portfolio across primary care to rare disease.

Piramal Pharma On ADC-Making Edge, BIOSECURE Act, $2Bn-Mark Strategy

In a video interview, Nandini Piramal, chairperson of Piramal Pharma, speaks with Scrip about a focus on on-patent products, an integrated ADC offering, a measured approach to the proposed BIOSECURE Act and the company’s strategy to double revenue to about $2bn

BIOSECURE Act – Which Indian Firms Are Best Placed To Help Plug Pharma’s Sourcing Gaps?

Indian CMOs, CDMOs and CRDMOs are expanding capacity and making leadership moves ahead of the BIOSECURE Act, anticipating demand from big pharma and budding biotechs. Scrip brings details on leading Indian firms which could be potential go-to suppliers for US companies affected by the proposed Act